Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients

References

• Hong S, Hahn J, Lee J, Bae S, Youn M. 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67-Ga scan. Yonsi Medical Journal 2003; 44: 779–786
   PubMed Web of Science ®Google Scholar
• Friedberg J, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist 2003; 8: 438–447
   PubMed Web of Science ®Google Scholar
• Lavely W C, Delbeke D, Greer J P, Morgan D S, Byrne D W, Price R R, Hallahan D E. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. International Journal of Radiation Oncology, Biology & Physics 2003; 57: 307–315
   PubMed Web of Science ®Google Scholar
• Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Leonard J P, Kuji I, Coleman M, Vallabhajosula S, Goldsmith S. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879–888
   PubMed Web of Science ®Google Scholar
• Blum R H, Seymour J F, Wirth A, MacManus M, Hicks R J. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma 2003; 4: 43–49
   PubMedGoogle Scholar
• Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biotechnology & Radiophysics 2001; 16: 297–304
   PubMed Web of Science ®Google Scholar
• Hoffman M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64: 336–340
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is 18F FDG-PET a valid alternative to conventional methods?. Journal of Clinical Oncology 2001; 19: 414–419
   PubMed Web of Science ®Google Scholar
• Schaefer N G, Hany T F, Taverna C, Seifert B, Stumpe K DM, von Schulthess G K, Goerres G W. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-Do we need contrast enhanced CT?. Radiology 2004; 232: 823–829
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. British Journal of Cancer 2004; 91: 850–854
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Annals of Oncology 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mikhaeel N G, Fields P A, Nunan T, Timothy A R. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology 2005; 16: 1160–1168
   PubMed Web of Science ®Google Scholar
• Schiepers C, Filmont J E, Czerin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. European Journal of Nuclear Medicine & Molecular Imaging 2003; 30: 82–88
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with 18Ffluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. British Journal of Haematology 2001; 115: 272–278
   PubMed Web of Science ®Google Scholar
• Mikhaeel N, Timothy A, O'Doherty M, Hain S, Maisey M. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leukemia & Lymphoma 2000; 39: 543–553
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard J P, Kuji I, Zoe H, Goldsmith S. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of Nuclear Medicine 2002; 43: 1018–1027
   PubMed Web of Science ®Google Scholar